StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
CymaBay Therapeutics
32.18
-0.16%
 

CBAY

 

CymaBay Therapeutics

$ 32.18

 
-$0.05 | -0.16%
 
 
Open
$ 32.24
 
 
MKT CAP
$ 3.69B
 
High
$ 32.30
 
 
VOL
$ 1.79M
 
Low
$ 32.17
 
 
AVG VOL
$ 5.88M
 
 
 

CBAY Stock Analysis

  Login to display CymaBay Therapeutics (CBAY) recommendation from the last 90 days from financial news and social media.
 
 

CBAY Total Score

 
 

Strengths

CBAY Rewards

 Analysts raised price target

CBAY Rewards

 Outperform the market

 

Risk Analysis

CBAY Risk Analysis

 Downgraded on weak valued

 
 

Chart

 
 

23.99

20.86

13.61

8.91

 
 
1month
3month
6month
1year
 
Total Return
CBAY
vs.
S&P500
 

 
1-week Return
-0.43%
 
+1.04%
 
 
5-week Return
+39.73%
 
+4.91%
 
 
10-week Return
+42.20%
 
+7.60%
 
 
 

CBAY Risk Level

This Indicator assigning CBAY risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
CBAY Risk Level
LOW
HIGH

Risk Volatility

 

CBAY has Low Risk Level

Click here to check what is your level of risk

 

CBAY Analysts Opinion

CBAY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

CBAY Earnings Sentiment

 Below analyst estimate

 
 

Rating

×
 

Rating

2.00
 

CBAY Rating Sentiment

 Downgraded on weak valued

 

Momentum

×
 

Momentum

4.00
 

CBAY Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

4.00
 

CBAY Future Sentiment

 Analysts raised price target

CBAY Future Sentiment

 Outperform the market

 
 

CBAY Analysts Opinion

CBAY Analysts opinion is negative and has getting worse from the past 3 months

 

CBAY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
78%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
100%
67%
 
On Track
On Track
On Track
 

CBAY Street Opinion 

CBAY Street view is extremely ish and have positive views on the near-term outlook

 

CBAY Performance Sentiment

Sentiments overview associated with CBAY events and the stock performance.
 
78%
17%
Positive
Negative
14 out of 18
events present
3 out of 18
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

CBAY Earnings

The TTM reflects 12-month period, providing review of CBAY financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
-
 
 
Operating Exp
94
93
88
+3.35%
 
 
Operating Inc
-94
-93
-88
-
 
 
Net Interest Inc
-12
-13
-2
-
 
 
Interest Exp
13
15
3
+108.17%
 
 
Interest Inc
1
2
-
 
 
Other Income
-
-
-
-
 
 
EPS
-1.53
-1.21
-1.27
-
 
 
Next Earnings Date: Mar 14, 2024
 
 
Similar to CBAY
Total Score
Close Price
%
Change

GILD

Gilead Sciences

2.88

72.25

-0.08%

 
 
 
Highlights
Last Modify
Price
% Change

 
Weak Earnings
This Week
32.27
-0.15%
 
Downgrade
1 Week Ago
32.20
+0.06%
 
Price Target Reached
2 Weeks Ago
32.12
-0.28%
 
Options Activity
2 Weeks Ago
32.21
+25.38%
 
New Product
2 Month Ago
24.23
+1.98%
 
 
 
joker
 
 
 
StocksRunner

Explore our CBAY Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our CBAY Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

CBAY Rewards

 Analysts raised price target

CBAY Rewards

 Outperform the market

 

Risk Analysis

 

CBAY Risk Analysis

 Downgraded on weak valued

 
 
 

CBAY Risk Level

 
 
 

The Indicator assigning CBAY risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
CBAY Risk Level
LOW
HIGH

Risk Volatility

 

CBAY has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

CBAY

 

CymaBay Therapeutics

$ 32.18

 
-$0.05 | -0.16%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 32.24
 
 
MKT CAP
$ 3.69B
 
High
$ 32.30
 
 
VOL
$ 1.79M
 
Low
$ 32.17
 
 
AVG VOL
$ 5.88M
 
 
 

CBAY Analysis

  Sign in to view CymaBay Therapeutics (CBAY) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

23.99

20.86

13.61

8.91

 
 
1month
3month
6month
1year
 
Total Return
CBAY
vs.
S&P500
 

 
1-week Return
-0.43%
 
+1.04%
 
 
5-week Return
+39.73%
 
+4.91%
 
 
10-week Return
+42.20%
 
+7.60%
 
 
 

CBAY Analysts Opinion

CBAY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

CBAY Earnings Sentiment

 Below analyst estimate

 
 

Rating

×
 

Rating

2.00
 

CBAY Rating Sentiment

 Downgraded on weak valued

 

Momentum

×
 

Momentum

4.00
 

CBAY Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

4.00
 

CBAY Future Sentiment

 Analysts raised price target

CBAY Future Sentiment

 Outperform the market

 
 

CBAY Analysts Opinion

CBAY Analysts opinion is negative and has getting worse from the past 3 months

 

CBAY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
78%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
100%
67%
 
On Track
On Track
On Track
 

CBAY Street Opinion 

CBAY Street view is extremely ish and have positive views on the near-term outlook

 
CBAY Performance Sentiment
Sentiments overview associated with CBAY events and the stock performance.
 
78%
17%
Positive
Negative
14 out of 18
events present
3 out of 18
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

CBAY Earnings

The TTM data reflects the most recent 12-month period, providing overview of CBAY financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
-
 
 
Operating Exp
94
93
88
+3.35%
 
 
Operating Inc
-94
-93
-88
-
 
 
Net Interest Inc
-12
-13
-2
-
 
 
Interest Exp
13
15
3
+108.17%
 
 
Interest Inc
1
2
-
 
 
Other Income
-
-
-
-
 
 
EPS
-1.53
-1.21
-1.27
-
 
 
Next Earnings Date: Mar 14, 2024
 
Highlights
Last Modify
Price
% Change

 
Weak Earnings
This Week
32.27
-0.15%
 
Downgrade
1 Week Ago
32.20
+0.06%
 
Price Target Reached
2 Weeks Ago
32.12
-0.28%
 
Options Activity
2 Weeks Ago
32.21
+25.38%
 
New Product
2 Month Ago
24.23
+1.98%
 
 
CBAY Latest News Feed

CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss Misses Revenue Estimates. CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate

Wed Feb 28, 2024

Earnings

CymaBay Reports Fourth Quarter and Year Ended December 31 2023 Financial Results and Provides Corporate Update. Gilead Sciences Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. 

Wed Feb 28, 2024

Activity

CymaBay Therapeutics GAAP EPS of -$0.35 misses by $0.04.

Wed Feb 28, 2024

Earnings

CymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37. The average one-year price target for CymaBay Therapeutics (NasdaqGS:CBAY) has been revised to 31.36 / share. This is an increase of 12.84% from the prior

Sat Feb 24, 2024

Potential

The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBays Seladelpar in Primary Biliary Cholangitis. - Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-rep

Wed Feb 21, 2024

Activity

Leerink Partners Downgrades CymaBay Therapeutics (CBAY). Fintel reports that on February 20 2024 Leerink Partners downgraded their outlook for CymaBay Therapeutics (NasdaqGS:CBAY) from Outperform to Market Perform .

Tue Feb 20, 2024

Potential
Rating

CymaBay Therapeutics Reaches Analyst Target Price. In recent trading shares of CymaBay Therapeutics Inc (Symbol: CBAY) have crossed above the average analyst 12-month target price of $28.45 changing hands for $32.21/share. When a stock reaches

Tue Feb 13, 2024

Potential

Gilead (GILD) to Buy CBAY for $4.3B Add PBC Drug to Pipeline. Gilead Sciences Inc. GILD announced that it will acquire clinical-stage biopharmaceutical company CymaBay Therapeutics Inc. CBAY fo

Tue Feb 13, 2024

Activity

Notable Monday Option Activity: CBAY TTD OSW. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in CymaBay Therapeutics Inc (Symbol: CBAY) where a total volume of 10365 contract

Mon Feb 12, 2024

Momentum

Dow Surges Over 150 Points. Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B. United States stocks traded higher midway through trading with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38856.99 while the NAS

Mon Feb 12, 2024

Activity

Drugmaker Gilead to acquire CymaBay for $4.3 bln. United States drugmaker Gilead Sciences agreed to acquire CymaBay Therapeutics for $4.3 billion on Monday adding a treatment for chronic liver disease to its portfolio.

Mon Feb 12, 2024

Activity

Gilead To Acquire CymaBay. To Enhance Revenue Growth Upon Approval Of Seladelpar. (RTTNews) - Gilead Sciences Inc. (GILD) and CymaBay Therapeutics Inc. (CBAY) announced a definitive agreement under which Gilead will acquire CymaBay a clinical-st

Mon Feb 12, 2024

Activity

CymaBay Announces FDA Acceptance Of NDA Priority Review For Seladelpar. Stock Up 24%. (RTTNews) - CymaBay Therapeutics Inc. (CBAY) announced on Monday that the United States Food and Drug Administration has accepted its New Drug Application or N

Mon Feb 12, 2024

Momentum

CymaBays stock surges as Gilead reaches $4.3 billion deal for liver-drug developer. CymaBay Therapeutics Inc. shares CBAY jumped 24% early Monday after Gilead Sciences Inc. GILD reached a $4.3 billion deal to acquire the liver-drug developer for $32.50 pe

Mon Feb 12, 2024

Activity

Gilead to acquire CymaBay for $32.50/share in cash.

Mon Feb 12, 2024

Activity

cymabay announces inducement grants under nasdaq listing rule 5635(c)(4). newark calif. jan. 16 2024 (globe newswire) -- cymabay therapeutics inc. (nasdaq:) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other

Tue Jan 16, 2024

Activity

 
 
 
 
 

Score Tracker

 
 
 
Based on 18 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 20:54 Wall St. time
 
 

CBAY Total Score

 
 
 
 
 

Similar to CBAY

 
 
 
Symbol
Score
% Change

GILD

Gilead Sciences

2.88

-0.08%

72.25

 
 
 
 
 
 
StocksRunner

Discover CBAY Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of CBAY. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our CBAY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CBAY Stock trends

CBAY Stock performance

CBAY Stock analysis

CBAY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker